Physician profile
Michael E Rosenband
NPI 1215941091
$9,615.71
in general payments reported to CMS, 2019-2025
39 companies · $1,067 in 2025
The $1,067 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $910 · 2021: $1,566 · 2022: $1,396 · 2023: $2,286 · 2024: $1,188 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,072 · Travel and Lodging: $459 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,072.49 |
| Travel and Lodging | $458.59 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,678.07 | 2019-2025 | Optis, Cardiomems, Xience Sierra |
| Novartis Pharmaceuticals Corporation | $1,117.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $704.19 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $630.34 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $526.35 | 2019-2022 | |
| Amgen INC. | $486.16 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.77 | 2019-2025 | Jardiance |
| Pfizer INC. | $427.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $344.54 | 2019-2025 | Wainua, Farxiga |
| Cvrx, INC. | $278.70 | 2021-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $254.42 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $220.64 | 2023-2025 | Rotapro, Watchman Flx |
| Chiesi USA, INC. | $175.18 | 2019-2023 | Kengreal, Cleviprex |
| Medtronic Vascular, INC. | $146.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $145.11 | 2019-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rosenband listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.